X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 39.0 22.1 176.4% View Chart
P/BV x 3.0 3.1 96.2% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-17
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs643176 365.3%   
Low Rs50379 640.5%   
Sales per share (Unadj.) Rs254.437.7 675.1%  
Earnings per share (Unadj.) Rs16.15.1 315.5%  
Cash flow per share (Unadj.) Rs29.86.7 442.9%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.642.5 457.3%  
Shares outstanding (eoy) m126.20158.23 79.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.4 66.7%   
Avg P/E ratio x35.725.0 142.7%  
P/CF ratio (eoy) x19.218.9 101.7%  
Price / Book Value ratio x2.93.0 98.5%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,30020,135 359.1%   
No. of employees `00013.31.2 1,154.8%   
Total wages/salary Rs m6,960703 989.7%   
Avg. sales/employee Rs Th2,413.55,176.2 46.6%   
Avg. wages/employee Rs Th523.2610.4 85.7%   
Avg. net profit/employee Rs Th152.4699.6 21.8%   
INCOME DATA
Net Sales Rs m32,1065,963 538.4%  
Other income Rs m22618 1,253.9%   
Total revenues Rs m32,3325,981 540.6%   
Gross profit Rs m4,4481,430 311.0%  
Depreciation Rs m1,730258 670.6%   
Interest Rs m241-26 -926.2%   
Profit before tax Rs m2,7031,216 222.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m675342 197.3%   
Profit after tax Rs m2,028806 251.6%  
Gross profit margin %13.924.0 57.8%  
Effective tax rate %25.028.1 88.8%   
Net profit margin %6.313.5 46.7%  
BALANCE SHEET DATA
Current assets Rs m17,3405,102 339.9%   
Current liabilities Rs m9,5592,385 400.7%   
Net working cap to sales %24.245.6 53.2%  
Current ratio x1.82.1 84.8%  
Inventory Days Days100150 66.9%  
Debtors Days Days57113 50.2%  
Net fixed assets Rs m20,7795,148 403.6%   
Share capital Rs m252158 159.5%   
"Free" reserves Rs m24,4996,556 373.7%   
Net worth Rs m24,5536,732 364.7%   
Long term debt Rs m3,517952 369.4%   
Total assets Rs m39,59510,388 381.2%  
Interest coverage x12.2-45.8 -26.7%   
Debt to equity ratio x0.10.1 101.3%  
Sales to assets ratio x0.80.6 141.3%   
Return on assets %5.77.5 76.3%  
Return on equity %8.312.0 69.0%  
Return on capital %10.514.6 71.8%  
Exports to sales %48.674.5 65.3%   
Imports to sales %14.224.8 57.5%   
Exports (fob) Rs m15,6174,441 351.7%   
Imports (cif) Rs m4,5711,477 309.4%   
Fx inflow Rs m15,6175,298 294.8%   
Fx outflow Rs m5,8281,772 328.8%   
Net fx Rs m9,7903,525 277.7%   
CASH FLOW
From Operations Rs m2,7641,274 217.0%  
From Investments Rs m-1,432-1,204 118.9%  
From Financial Activity Rs m-1,591-196 811.5%  
Net Cashflow Rs m-259-126 204.9%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jan 23, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - CIPLA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS